Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington's disease

Molecular and Cellular Neuroscience

Volumn 22, Issue 3, 2003, Pages 285-297

  Senatorov, Vladimir V ^a   Charles, Vinod ^b   Reddy, P H ^c   Tagle, Dan A ^b   Chuang, De Maw ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HUNTINGTIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CELL LOSS; CELL NUCLEUS; CELL TYPE; CONTROLLED STUDY; ENZYME LOCALIZATION; FLUORESCENCE; GLOBUS PALLIDUS; HIPPOCAMPUS; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOUSE; NEOCORTEX; NISSL STAINING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS;

EID: 0345701435     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-7431(02)00013-1     Document Type: Article

References (55)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anat. Rec. 94:1946;239-247.
2. Berry M.D., Boulton A.A. Glyceraldehyde-3-phosphate dehydrogenase and apoptosis. J. Neurosci. Res. 60:2000;150-154.
3. Burke J.R., Enghild J.J., Martin M.E., Jou Y.S., Myers R.M., Roses A.D., Vance J.M., Strittmatter W.J. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat. Med. 2:1996;347-350.
4. Butterworth N.J., Williams L., Bullock J.Y., Love D.R., Faull R.L., Dragunow M. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience. 87:1998;49-53.
5. Carlile G.W., Chalmers-Redman R.M., Tatton N.A., Pong A., Borden K.E., Tatton W.G. Reduced apoptosis after nerve growth factor and serum withdrawal conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer . Mol. Pharmacol. 57:2000;2-12.
6. Cattaneo E., Rigamonti D., Goffredo D., Zuccato C., Squitieri F., Sipione S. Loss of normal huntingtin function new developments in Huntington's disease research . Trends Neurosci. 24:2001;182-188.
7. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6:2000;797-801.
8. Chen R.W., Saunders P.A., Wei H., Li Z., Seth P., Chuang D.-M. Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis evidence that GAPDH is upregulated by p53 . J. Neurosci. 19:1999;9654-9662.
9. Chuang D.-M., Ishitani R. A role for GAPDH in apoptosis and neurodegeneration. Nat. Med. 6:1996;609-610.
10. Cooper A.J., Sheu K.F., Burke J.R., Strittmatter W.J., Blass J.P. Glyceraldehyde 3-phosphate dehydrogenase abnormality in metabolically stressed Huntington disease fibroblasts. Dev. Neurosci. 20:1998;462-468.
11. Dastoor Z., Dreyer J.L. Potential role of nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase in apoptosis and oxidative stress. J. Cell Sci. 114:2001;1643-1653.
12. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90:1997;537-548.
13. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1997;1990-1993.
14. Di Prospero N.A., Tagle D.A. Normal and mutant huntingtin partners in crime . Nat Med. 6:2000;1208-1209.
15. Dragunow M., Faull R.L., Lawlor P., Beilharz E.J., Singleton K., Walker E.B., Mee E. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport. 6:1995;1053-1057.
16. Dunah A.W., Jeong H., Griffin A., Kim Y.M., Standaert D.G., Hersch S.M., Mouradian M.M., Young A.B., Tanese N., Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science. 296:2002;2238-2243.
17. Feldhaus L.M., Liedtke A.J. mRNA expression of glycolytic enzymes and glucose transporter proteins in ischemic myocardium with and without reperfusion. J. Mol. Cell. Cardiol. 30:1998;2475-2485.
18. Graven K.K., Farber H.W. Endothelial cell hypoxic stress proteins. J. Lab. Clin. Med. 132:1998;456-463.
19. Haddad M.S., Cummings J.L. Huntington's disease. Psychiatr. Clin. North. Am. 20:1997;791-807.
20. Hedreen J.C., Peyser C.E., Folstein S.E., Ross C.A. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci. Lett. 133:1991;257-261.
21. Heinsen H., Strik M., Bauer M., Luther K., Ulmar G., Gangnus D., Jungkunz G., Eisenmenger W., Gotz M. Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol. (Berl). 88:1994;320-333.
22. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72:1993;971-983.
23. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 23:1999;181-192.
24. Ishitani R., Chuang D.-M. Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons. Proc. Natl. Acad. Sci. USA. 93:1996;9937-9941.
25. Ishitani R., Kimura M., Sunaga K., Katsube N., Tanaka M., Chuang D.-M. An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J. Pharmacol. Exp. Ther. 278:1996;447-454.
26. Ishitani R., Sunaga K., Hirano A., Saunders P., Katsube N., Chuang D.-M. Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J. Neurochem. 66:1996;928-935.
27. Ito Y., Pagano P.J., Tornheim K., Brecher P., Cohen R.A. Oxidative stress increases glyceraldehyde-3-phosphate dehydrogenase mRNA levels in isolated rabbit aorta. Am. J. Physiol. 270:1996;H81-H87.
28. Johnson T.M., Yu Z.X., Ferrans V.J., Lowenstein R.A., Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA. 93:1996;11848-11852.
29. Kish S.J., Lopes-Cendes I., Guttman M., Furukawa Y., Pandolfo M., Rouleau G.A., Ross B.M., Nance M., Schut L., Ang L., DiStefano L. Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders. Arch. Neurol. 55:1998;1299-1304.
30. Koshy B., Matilla T., Burright E.N., Merry D.E., Fischbeck K.H., Orr H.T., Zoghbi H.Y. Spinocerebellar ataxia type-1 and spinobulbar muscular atrophy gene products interact with glyceraldehyde-3-phosphate dehydrogenase. Hum. Mol. Genet. 5:1996;1311-1318.
31. Kragten E., Lalande I., Zimmermann K., Roggo S., Schindler P., Muller D., van Oostrum J., Waldmeier P., Furst P. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J. Biol. Chem. 273:1998;5821-5828.
32. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cadigan B.A., Warzecki L., Tagle D.A., Reddy P.H., Cepeda C., Calvert C.R., Jokel E.S., Klapstein G.J., Ariano M.A., Levine M.S., DiFiglia M., Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J. Neurosci. 21:2001;9112-9123.
33. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:1996;493-506.
34. Mazzola J.L., Sirover M.A. Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts. J. Neurochem. 76:2001;442-449.
35. McEwen B.S. Stress and the aging hippocampus. Front. Neuroendocrinol. 20:1999;49-70.
36. Menalled L.B., Chesselet M.F. Mouse models of Huntington's disease. Trends Pharmacol. Sci. 23:2002;32-39.
37. Mitchell I.J., Cooper A.J., Griffiths M.R. The selective vulnerability of striatopallidal neurons. Prog. Neurobiol. 59:1999;691-719.
38. Omar A.I., Senatorov V.V., Hu B. Ethidium bromide staining reveals rapid cell dispersion in the rat dentate gyrus following ouabain-induced injury. Neuroscience. 95:2000;73-80.
39. Ona V.O., Li M., Vonsattel J.P., Andrews L.J., Khan S.Q., Chung W.M., Frey A.S., Menon A.S., Li X.J., Stieg P.E., Yuan J., Penney J.B., Young A.B., Cha J.H., Friedlander R.M. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature. 399:1999;263-267.
40. Petersen A., Mani K., Brundin P. Recent advances on the pathogenesis of Huntington's disease. Exp. Neurol. 157:1999;1-18.
41. Portera-Cailliau C., Hedreen J.C., Price D.L., Koliatsos V.E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 15:1995;3775-3787.
42. Reddy P.H., Charles V., Williams M., Miller G., Whetsell W.O. Jr., Tagle D.A. Transgenic mice expressing mutated full-length HD cDNA a paradigm for locomotor changes and selective neuronal loss in Huntington's disease . Philos. Trans. R. Soc. London B. Biol. Sci. 354:1999;1035-1045.
43. Reddy P.H., Williams M., Charles V., Garrett L., Pike-Buchanan L., Whetsell W.O. Jr., Miller G., Tagle D.A. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat. Genet. 20:1998;198-202.
44. Rosas H.D., Liu A.K., Hersch S., Glessner M., Ferrante R.J., Salat D.H., van der Kouwe A., Jenkins B.G., Dale A.M., Fischl B. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology. 58:2002;695-701.
45. Saunders P.A., Chalecka-Franaszek E., Chuang D.-M. Subcellular distribution of glyceraldehyde-3-phosphate dehydrogenase in cerebellar granule cells undergoing cytosine arabinoside-induced apoptosis. J. Neurochem. 69:1997;1820-1828.
46. Saunders P.A., Chen R.W., Chuang D.-M. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase isoforms during neuronal apoptosis. J. Neurochem. 72:1999;925-932.
47. Sawa A., Khan A.A., Hester L.D., Snyder S.H. Glyceraldehyde-3-phosphate dehydrogenase nuclear translocation participates in neuronal and nonneuronal cell death . Proc. Natl. Acad. Sci. USA. 94:1997;11669-11674.
48. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G.P., Davies S.W., Lehrach H., Wanker E.E. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 90:1997;549-558.
49. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., Copeland N.G., Price D.L., Ross C.A., Borchelt D.R. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8:1999;397-407.
50. Shashidharan P., Chalmers-Redman R.M., Carlile G.W., Rodic V., Gurvich N., Yuen T., Tatton W.G., Sealfon S.C. Nuclear translocation of GAPDH-GFP fusion protein during apoptosis. Neuroreport. 10:1999;1149-1153.
51. Sheline C.T., Choi D.W. Neuronal death in cultured murine cortical cells is induced by inhibition of GAPDH and triosephosphate isomerase. Neurobiol. Dis. 5:1998;47-54.
52. Sirover M.A. New insights into an old protein the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase . Biochim. Biophys. Acta. 1432:1999;159-184.
53. Tatton W.G., Chalmers-Redman R.M., Elstner M., Leesch W., Jagodzinski F.B., Stupak D.P., Sugrue M.M., Tatton N.A. Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling. J. Neural. Transm. Suppl. 60:2000;77-100.
54. Thomas L.B., Gates D.J., Richfield E.K., O'Brien T.F., Schweitzer J.B., Steindler D.A. DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp. Neurol. 133:1995;265-272.
55. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA. 97:2000;8093-8097.